Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Misonix (MSON) yesterday and set a price target of $20.00. The company’s shares closed last Thursday at $11.80.
According to TipRanks.com, Rose is a 4-star analyst with an average return of 8.3% and a 49.3% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Alphatec Holdings.
Misonix has an analyst consensus of Moderate Buy, with a price target consensus of $18.50, implying a 64.6% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $17.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.20 and a one-year low of $6.71. Currently, Misonix has an average volume of 52.86K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Misonix, Inc. is a medical device company, which engages in the design, development, manufacture and marketing of therapeutic ultrasonic medical devices. Its products include the bonescalpel cutting system, which is used for surgical procedures of the spine and on maxillofacial procedures; the sonastar surgical aspirator, which is used to emulsify and remove soft and hard tumors; the sonicone wound cleansing and debridement system, which offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells. The company’s ultrasonic medical devices are used in the following surgeries: spine, neuro, orthopedic, wound debridement, cosmetic, laparoscopic, and medical applications. The company was founded by Howard Alliger in 1959 and is headquartered in Farmingdale, NY.
